Quality ControlNCT05687461
Construction of a National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases
An observational study of Quality Control, run by China-Japan Friendship Hospital at 1 site in China.
Trial summary
1. Build a national diagnosis and treatment quality control platform for major respiratory diseases It will establish and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and form a three-level network of diagnosis and treatment quality control for major… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Quality Control
- How many people
- 10,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jul 2022to 31 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: People at high risk of VTE, people diagnosed with VTE
Who may be able to join
- For patients at high risk for VTE 1) Have an expected hospital stay of ≥72 hours for medical and/or surgical treatment II. For patients diagnosed with VTE
- 1) With clearly diagnosed of deep vein thrombosis or pulmonary thromboembolism
Who cannot join
- For patients at high risk for VTE
- VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment
- Requiring a full dose of anticoagulant treatment before enrollment (e.g., recent VTE, atrial fibrillation).
Trial locations and contacts
1 site in 1 country.
China1 site
China-Japanese Friendship Hosptial
Beijing, Beijing Municipality, 100029
About this study
Official title: Construction of a National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases and Technical Promotion of Standardized Diagnosis and Treatment Programs
- Build a national diagnosis and treatment quality control platform for major respiratory diseases It will establish and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and form a three-level network of diagnosis and treatment quality control for major respiratory diseases with a three-level system structure of "national, provincial and hospital".
- Promote standardized diagnosis and treatment techniques for major respiratory diseases Relying on the specialized disease collaboration group or innovative unit model, all-round and hierarchical precision training and teaching are carried out to popularize and promote standardized diagnosis and treatment technology schemes for major respiratory diseases, so as to achieve the homogenization of diagnosis and treatment level for major respiratory diseases.
Read the detailed description
- Build a national diagnosis and treatment quality control platform for major respiratory diseases Cooperate with the Medical Administration Administration of the National Health Commission, the Medical Administration Institute of the National Health Commission and the National Center for Respiratory Disease Medical Quality Control to integrate the existing diagnosis and treatment quality indicators and data from NCIS (National Medical Quality Management and Control Information Network) and HQMS (Hospital Quality Monitoring System), and determine the definition, data sources and collection rules of core quality control indicators. It has established and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and formed a three-level network of diagnosis and treatment quality control for major respiratory diseases with a three-level system structure of "national, provincial and hospital".
- To master the incidence trend and diagnosis and treatment quality of major respiratory diseases Through the big data integration and analysis function of the "National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases", the incidence trend and law of various major respiratory diseases are mastered. To understand the difference in the diagnosis and treatment quality of respiratory diseases in hospitals of different regions and levels, including the allocation of related resources (such as personnel, technology, equipment, information construction, etc.); The status of diagnosis and treatment ability (prevention, diagnosis, treatment, rehabilitation, etc.); Current burden of disease (e.g. morbidity, case fatality rate, average length of stay, average cost of stay, etc.)
- Promote standardized diagnosis and treatment techniques for major respiratory diseases Relying on the specialized disease collaboration group or innovative unit model, through online and offline academic conferences, continuing medical education, specialized training, visits and exchanges, case discussions, knowledge competitions, wechat public accounts and other new media means, regularly focus on "prevention, diagnosis, treatment, rehabilitation, management, quality control" and many other aspects. Comprehensive and hierarchical precision training and teaching should be carried out to popularize and promote standardized diagnosis and treatment technology schemes for major respiratory diseases, so as to achieve the homogenization of diagnosis and treatment levels for major respiratory diseases.
- Conditions
- Quality Control
- Being tested
- Build a national diagnosis and treatment quality control platform for major respiratory diseases
- Keywords
- Quality Control, Respiratory Diseases
- Medical subject headings
- Respiratory Tract Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Build a national diagnosis and treatment quality control platform for major respiratory diseasesOther
- Build a national diagnosis and treatment quality control platform for major respiratory diseases
- To master the incidence trend and diagnosis and treatment quality of major respiratory diseases
- Promotion of standardized diagnosis and treatment techniques for major respiratory diseases
| Study group | Role | What they receive |
|---|---|---|
| People at high risk for VTE | Patients who are admitted to the hospital for acute medical illness or surgery operations. Receives: Other: Build a national diagnosis and treatment quality control platform for major respiratory diseases | |
| People diagnosed with VTE | Patients who were clearly diagnosed with deep vein thrombosis or pulmonary thromboembolism. Receives: Other: Build a national diagnosis and treatment quality control platform for major respiratory diseases |
What is being measured
The primary outcome is the main question the study is designed to answer.
A respiratory quality control network platform has been established
A complete national quality control network platform for the diagnosis and treatment of major respiratory diseases with multi-source data has been built
Measured: 2025.01
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2023
- Study start1 Jul 2022
- Primary completion31 Dec 2022
- Study completion31 Jul 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Quality ControlStudies of the same condition, open and under way.
- More trials run by China-Japan Friendship HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 10,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- China-Japan Friendship Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhenguo Zhai,MD,PhD, China-Japan Friendship Hospital
- Investigators
- Zhai Zhenguo, Doctor, Principal investigator, Department of Respiratory and Critical Care Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05687461
- Sponsor's protocol ID
- 12100000400014014Y
- Status last verified
- Jan 2023
- First submitted
- 29 Dec 2022
- Last updated
- 18 Jan 2023
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Construction of a National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases and Technical Promotion of Standardized Diagnosis and Treatment Programs
- ClinicalTrials.gov ID
- NCT05687461
- Acronym / sponsor ID
- 12100000400014014Y
- Conditions
- Quality Control
- Keywords
- Quality Control, Respiratory Diseases
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- China-Japan Friendship HospitalUniversity, hospital or other
- Study start
- 1 Jul 2022 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 31 Jul 2025 (estimated)
- First posted
- 18 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Build a national diagnosis and treatment quality control platform for major respiratory diseases It will establish and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and form a three-level network of diagnosis and treatment quality control for major respiratory diseases with a three-level system structure of "national, provincial and hospital".
- Promote standardized diagnosis and treatment techniques for major respiratory diseases Relying on the specialized disease collaboration group or innovative unit model, all-round and hierarchical precision training and teaching are carried out to popularize and promote standardized diagnosis and treatment technology schemes for major respiratory diseases, so as to achieve the homogenization of diagnosis and treatment level for major respiratory diseases.
Detailed description
- Build a national diagnosis and treatment quality control platform for major respiratory diseases Cooperate with the Medical Administration Administration of the National Health Commission, the Medical Administration Institute of the National Health Commission and the National Center for Respiratory Disease Medical Quality Control to integrate the existing diagnosis and treatment quality indicators and data from NCIS (National Medical Quality Management and Control Information Network) and HQMS (Hospital Quality Monitoring System), and determine the definition, data sources and collection rules of core quality control indicators. It has established and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and formed a three-level network of diagnosis and treatment quality control for major respiratory diseases with a three-level system structure of "national, provincial and hospital".
- To master the incidence trend and diagnosis and treatment quality of major respiratory diseases Through the big data integration and analysis function of the "National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases", the incidence trend and law of various major respiratory diseases are mastered. To understand the difference in the diagnosis and treatment quality of respiratory diseases in hospitals of different regions and levels, including the allocation of related resources (such as personnel, technology, equipment, information construction, etc.); The status of diagnosis and treatment ability (prevention, diagnosis, treatment, rehabilitation, etc.); Current burden of disease (e.g. morbidity, case fatality rate, average length of stay, average cost of stay, etc.)
- Promote standardized diagnosis and treatment techniques for major respiratory diseases Relying on the specialized disease collaboration group or innovative unit model, through online and offline academic conferences, continuing medical education, specialized training, visits and exchanges, case discussions, knowledge competitions, wechat public accounts and other new media means, regularly focus on "prevention, diagnosis, treatment, rehabilitation, management, quality control" and many other aspects. Comprehensive and hierarchical precision training and teaching should be carried out to popularize and promote standardized diagnosis and treatment technology schemes for major respiratory diseases, so as to achieve the homogenization of diagnosis and treatment levels for major respiratory diseases.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| People at high risk for VTE | – | Other: Build a national diagnosis and treatment quality control platform for major respiratory diseasesPatients who are admitted to the hospital for acute medical illness or surgery operations. |
| People diagnosed with VTE | – | Other: Build a national diagnosis and treatment quality control platform for major respiratory diseasesPatients who were clearly diagnosed with deep vein thrombosis or pulmonary thromboembolism. |
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- People at high risk of VTE, people diagnosed with VTE
Key inclusion criteria (2 listed)
- For patients at high risk for VTE 1) Have an expected hospital stay of ≥72 hours for medical and/or surgical treatment II. For patients diagnosed with VTE
- 1) With clearly diagnosed of deep vein thrombosis or pulmonary thromboembolism
Key exclusion criteria (3 listed)
- For patients at high risk for VTE
- VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment
- Requiring a full dose of anticoagulant treatment before enrollment (e.g., recent VTE, atrial fibrillation).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Build a national diagnosis and treatment quality control platform for major respiratory diseases1. Build a national diagnosis and treatment quality control platform for major respiratory diseases 2. To master the incidence trend and diagnosis and treatment quality of major respiratory diseases 3. Promotion of standardized diagnosis and treatment techniques for major respiratory diseases | Other | People at high risk for VTE, People diagnosed with VTE |
Primary outcome
A respiratory quality control network platform has been established
Time frame: 2025.01
A complete national quality control network platform for the diagnosis and treatment of major respiratory diseases with multi-source data has been built
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jan 2023.
Related trials for Quality Control
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Recruiting
Effects of a Prebiotic-Probiotic Combination on Constipation Symptoms and Quality of Life
Constipation, Abdominal Pain
Not yet recruiting
Tizanidine Premedication Versus Placebo for Laryngeal Mask Airway Insertion and Recovery in Adults Undergoing Ambulatory Surgery
Airway Management
Enrolling by invitation
Dance-Based Exercise for Cancer-Related Fatigue in Breast Cancer Patients
Breast Neoplasms
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zhai Zhenguo, Doctor principal investigator
Department of Respiratory and Critical Care Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Quality Control, run by China-Japan Friendship Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
A respiratory quality control network platform has been established (time frame: 2025.01). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2023.